For the quarterly period ended September 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10765 UNIVERSAL HEALTH SERVICES, INC. (Exact name of registrant as specified in its charter) DELAWARE 23-2077891 (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR For the transition period from _______ to _______ PIONEER BANCORP, INC. (Exact Name of Company as Specified in its Charter) Maryland 001-38991 83-4274253 (State of Other Jurisdiction of (Commission File No.) (I.R.S. Employer Identification No.) 652 Albany Shaker Road, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 56-2020050 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 12770 High Bluff Drive Suite 150 San Diego, California 92130 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-51173 Gyre Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR Delaware 56-2020050 (State or Other Ju ...

Drug Development - The company is developing ateganosine, a dual mechanism drug candidate targeting lung cancer, with over 235,000 new cases expected in the US in 2024, representing 12% of all cancers [138]. - The Phase 2 trial (THIO-101) for ateganosine in advanced Non-Small Cell Lung Cancer (NSCLC) began in July 2022, with plans for accelerated approval filing in the US by 2026 [138]. - The company plans to initiate a Phase 3 pivotal trial (THIO-104) in 2025, comparing ateganosine with chemotherapy in up to 300 patients resistant to previous treatments [140]. - The company plans to initiate Phase 2 trials for ateganosine in hepatocellular carcinoma, colorectal cancer, and small cell lung cancer in 2026 [138]. - A clinical supply agreement with BeOne Medicines was established in January 2025 to assess ateganosine in combination with tislelizumab for three cancer indications [140]. - A new partial response was identified in a patient after 20 months of treatment in the Phase 2 THIO-101 clinical trial, defined as a decrease in tumor size of at least 30% [142]. - The median overall survival (OS) for patients in the THIO-101 trial was reported at 17.8 months as of May 15, 2025, with a 95% confidence interval lower bound of 12.5 months [141]. - The estimated median overall survival (OS) in the THIO-101 trial was 17.8 months, with a 95% confidence interval lower bound of 12.5 months [142]. Financial Performance - The company raised approximately $2.72 million from a private placement of 1,810,000 shares at $1.50 per share in February 2025 [140]. - Under the At The Market Offering Agreement, the company sold 2,086,312 shares at an average price of $1.81 per share, resulting in net proceeds of approximately $3.66 million [141]. - The company received gross proceeds of approximately $2.25 million from a private placement of 1,733,766 shares at a price of $1.30 per share [146]. - The net loss attributable to MAIA Biotechnology, Inc. shareholders for the three months ended September 30, 2025, was $8.90 million, a 225% increase from $2.74 million in the same period of 2024 [145]. - Research and development expenses increased by approximately $3.69 million (138%) from $2.67 million for the three months ended September 30, 2024, to $6.36 million for the same period in 2025 [145]. - General and administrative expenses rose by approximately $1.48 million (97%) from $1.52 million in Q3 2024 to $3.00 million in Q3 2025 [148]. - Total operating costs and expenses for the three months ended September 30, 2025, were $9.36 million, a 123% increase from $4.19 million in the same period of 2024 [145]. - Research and development expenses for the nine months ended September 30, 2025, were approximately $12.67 million, an increase of 80% from $7.04 million in the same period of 2024 [150]. - Other income (expense), net increased by approximately $8.92 million (115%) from a net loss of $7.73 million for the nine months ended September 30, 2024, to a net income of $1.19 million for the same period in 2025 [153]. Capital and Cash Management - As of September 30, 2025, the company's cash totaled approximately $10,892,000, an increase of approximately $1,290,000 compared to December 31, 2024 [154]. - The company reported a working capital of approximately $1,761,000, a decrease of approximately $4,561,000 compared to December 31, 2024 [154]. - For the nine months ended September 30, 2025, net cash used in operating activities was approximately $11,824,000, compared to $11,796,000 for the same period in 2024 [169]. - Net cash provided by financing activities was approximately $13,104,000 for the nine months ended September 30, 2025, compared to $13,331,000 for the same period in 2024 [174]. - The company issued and sold 2,496,318 shares of Common Stock at a price of $1.17 per share on March 14, 2024, generating gross proceeds of approximately $2.92 million [157]. - The company plans to allocate up to 90% of its corporate treasury reserves to acquire and hold Digital Assets, including Bitcoin and Ether, under the Digital Asset Treasury Plan adopted on October 6, 2025 [156]. - The company launched a new digital asset treasury strategy focused on top-tier cryptocurrency assets, with up to 90% of liquid assets authorized for investment in cryptocurrencies [146]. - For the nine months ended September 30, 2025, the effect of foreign currency exchange rate changes increased the cash balance by approximately $10,000 [172]. Going Concern and Capital Needs - The company has substantial doubt about its ability to continue as a going concern within one year after the issuance of its financial statements due to ongoing losses and lack of revenue [155]. - The company needs to raise additional capital to fund operations and develop new products, with no assurance that financing will be available on acceptable terms [168]. Corporate Structure - The company has established subsidiaries in Australia and Romania to conduct preclinical and clinical activities for its product candidates [139].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-9321 UNIVERSAL HEALTH REALTY INCOME TRUST (Exact name of registrant as specified in its charter) MARYLAND 23-6858580 (State or ...

Company Overview - Exzeo Group, Inc. is an emerging growth company as defined under the Securities Act of 1933[3]. Financial Reporting - HCI Group, Inc., the controlling shareholder of Exzeo, filed its Quarterly Report on Form 10-Q for Q3 2025 on November 7, 2025[5]. - Exzeo's financial information for the three and nine months ended September 30, 2025, is included in HCI's Q3 10-Q, but Exzeo has not yet released its own financial statements[5]. - Exzeo intends to file its Quarterly Report on Form 10-Q within 45 days following the effective date of its Registration Statement on Form S-1[5]. - The financial information provided by HCI was prepared in accordance with an insurance company presentation format[5]. - The report includes select financial information for Exzeo for the periods ended September 30, 2025, and 2024[9]. - The report is not deemed "filed" for purposes of the Exchange Act or incorporated by reference in any filing under the Securities Act[6]. - The report was signed by Brook Baker, General Counsel of Exzeo Group, Inc.[13]. Forward-Looking Statements - Forward-looking statements regarding Exzeo's future filings are subject to various risks and uncertainties[7]. - Exzeo disclaims all obligations to update any forward-looking statements made in the report[7].

Financial Performance - Arcadia reported product revenues of $1,302,000 for the three months ended September 30, 2025, a decrease of 15% compared to $1,537,000 in the same period of 2024[133]. - The company recorded a net income of $856,000 from continuing operations for Q3 2025, a significant improvement compared to a net loss of $1,182,000 in Q3 2024[133]. - Arcadia's other income surged to $1,698,000 in Q3 2025, compared to only $15,000 in Q3 2024, marking a 11220% increase[133]. - Product revenues decreased by $235,000, or 15%, during the three months ended September 30, 2025, compared to the same period in 2024[134]. - Product revenues increased by $128,000, or 3%, during the nine months ended September 30, 2025, driven entirely by Zola coconut water sales[145]. Operating Expenses - Total operating expenses decreased by 26% to $2,454,000 in Q3 2025 from $3,297,000 in Q3 2024, driven by a 30% reduction in selling, general and administrative expenses[133]. - Research and development expenses were eliminated in Q3 2025, down from $24,000 in Q3 2024, reflecting a strategic shift in focus[133]. - Selling, general, and administrative expenses decreased by $671,000 during the three months ended September 30, 2025, primarily due to operating costs that were absent in 2025[137]. - Selling, general, and administrative expenses decreased by $1.6 million during the nine months ended September 30, 2025, compared to the same period in 2024[151]. Cash Flow and Liquidity - As of September 30, 2025, the company had cash and cash equivalents of $1.1 million, with a net loss of $1.0 million for the nine months ended September 30, 2025[159]. - Cash used in operating activities for the nine months ended September 30, 2025, was $3,878,000, compared to $7,418,000 for the same period in 2024[165][167]. - The company reported a net decrease in cash of $3,122,000 for the nine months ended September 30, 2025, compared to a decrease of $2,582,000 in 2024[165]. - Cash provided by investing activities for the nine months ended September 30, 2025, consisted of proceeds from the sale of intangible assets amounting to $750,000[168]. - Current assets as of September 30, 2025, were $8,387,000, while current liabilities were $2,285,000, resulting in a working capital surplus of $6,102,000[164]. Discontinued Operations - The company experienced a 100% increase in net loss from discontinued operations, reporting no loss in Q3 2025 compared to a loss of $430,000 in Q3 2024[133]. Strategic Transactions - Arcadia sold its non-GMO Resistant Starch durum wheat trait to Corteva for $4.0 million, retaining certain rights to use the trait[111]. - The company sold the GoodWheat™ brand to Above Food Corp. for net consideration of $3.7 million, resulting in a loss of $1,500 during Q2 2024[112]. - Arcadia entered into a Securities Exchange Agreement to issue shares of common stock to the limited partners of Roosevelt, resulting in a 90% ownership for the partners post-transaction[113]. Risks and Future Outlook - The company may seek additional funding through debt or equity financings, which could result in dilution for existing shareholders[162]. - If the company cannot secure adequate funding, it may be forced to reduce spending, extend payment terms, liquidate assets, or initiate bankruptcy proceedings[163]. - The market price of AFII common stock is very volatile, and there are no assurances regarding the net proceeds from potential sales of AFII shares[162]. Accounting and Estimates - Critical accounting estimates include revenue recognition, provision for income taxes, and net realizable value of inventory[172].

Financial Performance - Net earnings for the three months ended September 30, 2025, were $52,267 thousand, a decrease of 5.0% from $55,308 thousand in 2024[15]. - Comprehensive earnings for the nine months ended September 30, 2025, were $295,980 thousand, compared to $234,671 thousand in 2024, reflecting an increase of 26.1%[16]. - Net earnings for the period reached $161.19 million, reflecting strong performance[21]. - Net earnings for the nine months ended September 30, 2025, were $180,270,000, an increase of 11.5% compared to $161,190,000 for the same period in 2024[23]. - Net earnings for Q3 2025 were $52.27 million, down from $55.31 million in Q3 2024, with diluted earnings per share at $0.36 compared to $0.39[173]. - Year-to-date earnings growth for 2025 is nearly 12% compared to 2024, despite a $21.55 million credit loss due to fraudulent activity[173]. Asset and Loan Growth - Total assets increased to $14,841,528 thousand as of September 30, 2025, up from $13,582,932 thousand in 2024, representing a growth of 9.3%[12]. - Total loans held-for-investment increased to $8,243,625,000 as of September 30, 2025, up from $7,723,191,000 in 2024, representing a growth of 6.7%[85]. - Total deposits increased to $12,846,248 thousand as of September 30, 2025, compared to $11,755,861 thousand in 2024, an increase of 9.3%[12]. - Total loans held-for-investment as of September 30, 2024, amounted to $8,244 million, an increase from $7,991 million in 2023, reflecting a growth of approximately 3.2%[104]. Income and Expenses - Total interest income for the three months ended September 30, 2025, was $179,692 thousand, compared to $159,958 thousand in 2024, reflecting an increase of 12.3%[15]. - Total noninterest income for the nine months ended September 30, 2025, was $97,366 thousand, up from $93,012 thousand in 2024, marking a growth of 4.8%[15]. - Total noninterest expense for the first nine months of 2025 was $215.74 million, up from $194.97 million in the same period of 2024, indicating an increase of 10.6%[197]. - Salaries, commissions, and employee benefits for the first nine months of 2025 totaled $127.32 million, an increase of 14.0% from $111.65 million in 2024[198]. Credit Loss Provisions - The provision for credit losses increased to $24,435 thousand for the three months ended September 30, 2025, compared to $6,123 thousand in 2024, indicating a significant rise in credit loss provisions[15]. - Provision for credit losses increased significantly to $31,095,000 in 2025 from $12,817,000 in 2024, indicating a rise in expected credit losses[23]. - The allowance for credit losses at the end of September 2025 was $105,958,000, compared to $99,936,000 in 2024, reflecting an increase of 6.8%[85]. Shareholder Returns - Dividends per share increased to $0.19 for the three months ended September 30, 2025, compared to $0.18 in 2024, representing a growth of 5.6%[15]. - Cash dividends declared were $0.54 per share, totaling $77.20 million[21]. - Cash dividends declared increased to $0.56 per share, amounting to $80.25 million[21]. Investment and Securities - The company reported an unrealized gain of $73.48 million in available-for-sale investment securities, net of related income taxes[21]. - As of September 30, 2025, the total fair value of available-for-sale securities was $5,260,813,000, down from $4,612,299,000 as of September 30, 2024[78]. - The total amortized cost basis of available-for-sale securities was $5,651,768,000 as of September 30, 2025, with unrealized losses amounting to $413,930,000[78]. Risk Management and Loan Quality - The company has categorized its loans into five risk categories, with ongoing assessments to adjust ratings based on credit quality changes[96][97]. - Loans rated as "special mention" indicate financial weaknesses but are not expected to incur significant losses in the short term[98]. - The overall strategy includes continuous monitoring and adjustment of credit risk ratings to reflect the inherent risks in the loan portfolio[97]. Operational Metrics - Return on average assets for Q3 2025 was 1.44%, down from 1.66% in Q3 2024; return on average equity was 11.85%, down from 14.00%[174]. - The efficiency ratio improved to 45.33% for the first nine months of 2025, compared to 47.39% in the same period of 2024, reflecting better operational efficiency[197]. - The yield on earning assets increased by 16 basis points, while the rate paid on interest-bearing liabilities decreased by 23 basis points in Q3 2025 compared to Q3 2024[178].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 28, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission file number: 1-2207 THE WENDY'S COMPANY (Exact name of registrant as specified in its charter) Delaware 38-0471180 (I.R. ...